Search research articles
Contact Us
Filters
Showing results (71-80 of 83) with videos related to
Page
of 9
Sort By:
The New England Journal of Medicine
|
June 7, 2021
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
Ferdinandos Skoulidis, Bob T Li, Grace K Dy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 12, 2020
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.
Journal of Hematology & Oncology
|
June 6, 2025
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies
Quchang Ouyang, Jordi Rodon, Yan Liang, et al.
The New England Journal of Medicine
|
October 23, 2023
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer
John V Heymach, David Harpole, Tetsuya Mitsudomi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 30, 2025
Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC
Timothy F Burns, Natraj Reddy Ammakkanavar, Antoine Hollebecque, et al.
The New England Journal of Medicine
|
October 4, 2018
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 10, 2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)
Marcin Kowanetz, Wei Zou, Scott N Gettinger, et al.
Nature Communications
|
March 13, 2026
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study
Yonina R Murciano-Goroff, Antoine Hollebecque, Rebecca S Heist, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2018
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R Brahmer, Christina Lacchetti, Bryan J Schneider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
Bryan J Schneider, Jarushka Naidoo, Bianca D Santomasso, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 83) with videos related to
Sort By:
Page
of 9
The New England Journal of Medicine
|
June 7, 2021
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
Ferdinandos Skoulidis, Bob T Li, Grace K Dy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 12, 2020
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.
Journal of Hematology & Oncology
|
June 6, 2025
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies
Quchang Ouyang, Jordi Rodon, Yan Liang, et al.
The New England Journal of Medicine
|
October 23, 2023
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer
John V Heymach, David Harpole, Tetsuya Mitsudomi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 30, 2025
Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC
Timothy F Burns, Natraj Reddy Ammakkanavar, Antoine Hollebecque, et al.
The New England Journal of Medicine
|
October 4, 2018
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 10, 2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)
Marcin Kowanetz, Wei Zou, Scott N Gettinger, et al.
Nature Communications
|
March 13, 2026
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study
Yonina R Murciano-Goroff, Antoine Hollebecque, Rebecca S Heist, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2018
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R Brahmer, Christina Lacchetti, Bryan J Schneider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
Bryan J Schneider, Jarushka Naidoo, Bianca D Santomasso, et al.
Page
of 9